{"id":"W2913605978","doi":"10.1016/j.ejvs.2018.11.008","title":"PLX-PAD Cell Treatment of Critical Limb Ischaemia: Rationale and Design of the PACE Trial","year":2019,"lang":"en","type":"article","venue":"European Journal of Vascular and Endovascular Surgery","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":44,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Horizon 2020; Bayer Canada; AstraZeneca Schweiz; Terumo BCT; United States - Israel Binational Agricultural Research and Development Fund; Dan Jansen Foundation; Fresenius Biotech; Amgen; Pfizer; Merck; Bristol-Myers Squibb; Mitsubishi International Corporation","keywords":"Medicine; Clinical endpoint; Clinical trial; Tolerability; Placebo; Critical limb ischemia; Amputation; Surgery; Internal medicine; Adverse effect; Vascular disease; Arterial disease; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001067698,0.0001384851,0.0003622271,0.00005125567,0.00004493745,0.00001234693,0.00009636585,0.00004811718,0.00002072039],"category_scores_gemma":[0.0001257545,0.00009048361,0.0006656123,0.00006162026,0.0001338936,0.000009135246,0.0000521744,0.00005485173,0.000001119952],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000007550651,"about_ca_system_score_gemma":0.0001012005,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003979324,"about_ca_topic_score_gemma":3.053426e-7,"domain_scores_codex":[0.9984586,0.0005845554,0.0004246649,0.0001682273,0.00023138,0.0001326095],"domain_scores_gemma":[0.9991578,0.0001348021,0.0002246853,0.000276867,0.0001328692,0.0000729949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01276924,0.002203772,0.03576169,0.0007726921,0.004016864,0.0001427013,0.001044367,0.002883553,0.9167668,0.0002538444,0.004362596,0.01902187],"study_design_scores_gemma":[0.04676105,0.008297475,0.03806695,0.0004188007,0.001746424,0.0006276049,0.0007531913,0.0001788772,0.7802615,0.00008773391,0.1218263,0.000974104],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9615893,0.034048,0.003650606,0.00006881319,0.0002898967,0.0002070319,0.000006596097,0.000001252535,0.0001385293],"genre_scores_gemma":[0.990618,0.008398251,0.0005916431,0.00003841587,0.0002496729,0.000001964318,0.000003391979,0.00002258672,0.00007605485],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1365053,"threshold_uncertainty_score":0.3689815,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02337146066055147,"score_gpt":0.2326471690357974,"score_spread":0.2092757083752459,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}